Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac.
Conclusions: Prostate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy at the time of reference imaging and demonstrate stable anatomy throughout the course of their treatment. For patients with critical OARs abutting target volumes on their reference image we have demonstrated the potential for a target dose coverage improvement for MRgART compared to C-arm linac treatment. PMID: 32395640 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 14, 2020 Category: Cancer & Oncology Authors: Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J, Goodwin E, Herbert T, Lawes R, McNair H, McQuaid D, Mohajer J, Nilawar R, Pathmanathan A, Smith G, Hanson I, Nill S, Oelfke U Tags: Clin Transl Radiat Oncol Source Type: research
Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
Conclusion: Focal salvage HDR brachytherapy may provide good biochemical control with a low risk of severe toxicity. Further evaluation within clinical trials are needed to establish its role in the management of locally recurrent prostate cancer. PMID: 32368626 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 7, 2020 Category: Cancer & Oncology Authors: Slevin F, Hodgson S, Rodda SL, Bownes P, Bottomley D, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM Tags: Clin Transl Radiat Oncol Source Type: research
Ligand-Mediated Targeting of Cytokine Interleukin-27 Enhances Its Bioactivity In Vivo.
We describe our findings on the effects of targeted IL-27 gene delivery on prostate cancer cells in vitro and in vivo and how the targeting enhances bioactivity of the IL-27 cytokine. We applied the IL-27 gene delivery protocol utilizing sonoporation (sonodelivery) with the goal of reducing prostate tumor growth in an immunocompetent TC2R C57/BL6 model. The reduction in tumor growth and effector cellular profiles implicate targeted IL-27 as more effective than an untargeted version of IL-27 in promoting bioactivity, as assessed by STAT1 and IFN-γ reporter genes. Moreover, enhanced antitumor effects and sign...
Source: Clinical Prostate Cancer - May 1, 2020 Category: Cancer & Oncology Authors: Figueiredo ML, Figueiredo Neto M, Salameh JW, Decker RE, Letteri R, Chan-Seng D, Emrick T Tags: Mol Ther Methods Clin Dev Source Type: research
Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Abstract The aim of the present study was to investigate the impact of the combined use of corticosteroid on adverse events (AEs) induced by enzalutamide (Enz) in patients with metastatic castration-resistant prostate cancer (mCRPC). The cohort of the present study included 121 consecutive patients with mCRPC who sequentially received androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and Enz, in any order, without prior docetaxel therapy. Detailed assessments of AEs during treatment with Enz were conducted according to whether or not corticosteroid was administered. Of these patients, 63 and ...
Source: Clinical Prostate Cancer - April 8, 2020 Category: Cancer & Oncology Authors: Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H Tags: Mol Clin Oncol Source Type: research
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09.
Conclusions: The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12 months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted. PMID: 32258443 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 8, 2020 Category: Cancer & Oncology Authors: Mishra MV, Khairnar R, Bentzen SM, Larson G, Tsai H, Sinesi C, Vargas C, Laramore G, Rossi C, Rosen L, Sun K, Hartsell W Tags: Clin Transl Radiat Oncol Source Type: research
Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer.
Conclusions: Current RT with RTOG-based nodal fields for PCN+ provides good in-field tumour control, but frequent out-field nodal recurrences suggest missed microscopic locations. Expanding elective fields to include the aorta bifurcation may prolong recurrence-free survival. Future research must address whether the potential benefits of this strategy outbalance additional toxicity. PMID: 32154392 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 12, 2020 Category: Cancer & Oncology Authors: Liskamp CP, Donswijk ML, van der Poel HG, Schaake EE, Vogel WV Tags: Clin Transl Radiat Oncol Source Type: research
Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
Abstract The important conclusion that ctDNA is a mediocre proxy for liquid biopsies of tumor tissues for early detection was reached after new data were published recently in Nature Genetics. These data have shown that most mutations found in ctDNA are not related to tumor tissues but rather to the precancerous condition clonal hematopoiesis. Previously, our group has analyzed the sensitivity of the ctDNA test for early detection of cancer and concluded that the achievable sensitivity, especially for small tumors, is not enough to have clinical value. Now, the new data have shown a serious compromise in specifici...
Source: Clinical Prostate Cancer - March 11, 2020 Category: Cancer & Oncology Authors: Fiala C, Diamandis EP Tags: Clin Chem Lab Med Source Type: research
Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation.
CONCLUSION: A decrease of nuclear LCoR expression in line with an increase of dedifferentiation of CIN can be observed. Nuclear LCoR overexpression correlates with CIN II progression indicating a prognostic value of LCoR in cervical intraepithelial neoplasia. Nuclear and cytoplasmic RIP140 expression increases significantly with higher grading of cervical intraepithelial neoplasia underlining its potential role in the development of pre-cancerous lesions. These findings support the relevance of LCoR and RIP140 in the tumorigenesis indicating a possible role of LCoR and RIP140 as targets for novel therapeutic approaches in ...
Source: Clinical Prostate Cancer - March 10, 2020 Category: Cancer & Oncology Authors: Vogelsang TLR, Schmoeckel E, Kuhn C, Blankenstein T, Temelkov M, Heidegger H, Kolben TM, Kolben T, Mahner S, Mayr D, Jeschke U, Vattai A Tags: J Cancer Res Clin Oncol Source Type: research
Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial.
Abstract OBJECTIVE: The aim of this analysis is to evaluate the relative weight of different epidemiological risk factors on the development of different breast cancer subtypes (i.e. luminal, Her2+ overexpressed or triple negative). METHODS: De-identified datasets of female participants recruited within the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial were accessed. Multivariate Cox regression analysis was utilized to assess factors affecting the development of breast cancer (regardless of subtype). Additional multivariate analyses were conducted to assess factors affecting the development of t...
Source: Clinical Prostate Cancer - March 10, 2020 Category: Cancer & Oncology Authors: Abdel-Rahman O, Tang PA, Cheung WY Tags: Clin Transl Oncol Source Type: research
Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
in CM Abstract Lineage plasticity, the ability of cells to transition from one committed developmental pathway to another, has been proposed as a source of intratumoural heterogeneity and of tumour adaptation to an adverse tumour microenvironment including exposure to targeted anticancer treatments. Tumour cell conversion into a different histological subtype has been associated with a loss of dependency on the original oncogenic driver, leading to therapeutic resistance. A well-known pathway of lineage plasticity in cancer - the histological transformation of adenocarcinomas to aggressive neuroendocrine derivativ...
Source: Clinical Prostate Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Triparna S, Rudin CM Tags: Nat Rev Clin Oncol Source Type: research
Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
Abstract From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term 'specific' has been used to characterize a histologic hallmark of overexpression in the membrane of most prostate cancer. Many PSMA ligands have been developed since the previous decade and have been used in several clinical trials and clinical studies. However, procedure, specification, protocol, interpretation criteria, radiation dose, and cost-effectiveness of PSMA ligands have not been fully explained. Regardless of worldwide use of p...
Source: Clinical Prostate Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Tateishi U Tags: Jpn J Clin Oncol Source Type: research
Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
Abstract Myeloid-derived suppressor cells with polymorphonuclear morphology (PMN-MDSCs) contribute to the progression and immune evasion of prostate cancer. However, the spatial distribution of tumor-infiltrating PMN-MDSCs in primary and metastatic prostate cancer, especially in the context of comparison between the epithelial and stromal compartments of the tumor, has not been characterized. Here, we describe a multicolor immunofluorescence staining study of 90 primary tumors, 37 lymph node metastases (all with matched primary tumors) and 35 bone metastases using archived samples. CD11b+ CD15+ cells were identifi...
Source: Clinical Prostate Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Wen J, Huang G, Liu S, Wan J, Wang X, Zhu Y, Kaliney W, Zhang C, Cheng L, Wen X, Lu X Tags: J Pathol Clin Res Source Type: research
Genome-wide plasma DNA methylation features of metastatic prostate cancer.
Abstract Tumor DNA circulates in the plasma of cancer patients admixed with DNA from noncancerous cells. The genomic landscape of plasma DNA has been characterized in metastatic castration-resistant prostate cancer (mCRPC) but the plasma methylome has not been extensively explored. Here, we performed next-generation sequencing (NGS) on plasma DNA with and without bisulfite treatment from mCRPC patients receiving either abiraterone or enzalutamide in the pre- or post-chemotherapy setting. Principal component analysis on the mCRPC plasma methylome indicated that the main contributor to methylation variance (principa...
Source: Clinical Prostate Cancer - March 9, 2020 Category: Cancer & Oncology Authors: Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini GM, Kleftogiannis D, Jayaram A, Sandhu S, Wong SQ, Benelli M, Salvi S, Gurioli G, Feber A, Pereira MB, Wingate AM, Gonzalez-Billalebeita E, De Giorgi U, Demichelis F, Lise S, Attard G Tags: J Clin Invest Source Type: research
68Ga-Prostate-Specific Membrane Antigen Uptake in a Pancreatic Neuroendocrine Tumor.
We present a 60-year-old man with known prostate cancer treated with robot-assisted radical prostatectomy. Prostate-specific antigen levels did not decline accordingly, and a second Ga-PSMA PET/CT demonstrated a new focus with high Ga-PSMA uptake in the pancreatic tail. A subsequent CT scan did not display the lesion as a typical pancreatic tumor, and a spleen scintigraphy was also negative excluding an ectopic intrapancreatic accessory spleen. Ga-DOTATOC PET/CT showed uptake in the same area of the pancreatic tail consistent with a neuroendocrine tumor. This case illustrates that neuroendocrine tumors can be important pit...
Source: Clinical Prostate Cancer - March 7, 2020 Category: Cancer & Oncology Authors: Luong TV, Iversen P, Bouchelouche K, Arveschoug AK Tags: Clin Nucl Med Source Type: research
Solitary Penile Metastasis of Prostate Cancer on 18F-Fluciclovine PET/CT Imaging in a Patient With PSA of 1 ng/mL.
Abstract An 85-year-old asymptomatic man with suspected biochemical recurrence of prostate cancer underwent an F-fluciclovine PET/CT scan, which revealed a solitary suspicious tracer uptake in the dorsal right corporal body of the proximal pendulous penis. The patient underwent ultrasound-guided fine-needle aspiration of the penile lesion, which revealed metastatic prostate cancer. The patient had definitive external beam radiation therapy 3 years before the examination. At the time of scan, the prostatic-specific antigen (PSA) was only 1.0 ng/mL, although the PSA doubling time was 2.6 months. It is unusual to det...
Source: Clinical Prostate Cancer - March 7, 2020 Category: Cancer & Oncology Authors: Salavati A, Schik AN, Koksel Y, Gencturk M, Froelich JW Tags: Clin Nucl Med Source Type: research
Eye Symptoms in a Patient With Prostate Cancer.
d S Abstract A 66-year-old man with castration-resistant prostate cancer was evaluated with F-prostate-specific membrane antigen (PSMA) 1007 PET/CT, which revealed extensive PSMA-positive skeletal metastases in the skull, thorax, spine, pelvis, and extremities. He was then treated Lu-PSMA-617 therapy. Twenty-four-hour SPECT/CT revealed additional activity not seen with F-PSMA adjacent to his left eye. The lesion was biopsied after the first cycle due to pain. This activity was not visible on SPECT/CT after the second treatment cycle, and his eye pain has resolved. PMID: 32149800 [PubMed - as supplied by publi...
Source: Clinical Prostate Cancer - March 7, 2020 Category: Cancer & Oncology Authors: Kairemo K, Kangasmäki A, Joensuu T, Seregard S Tags: Clin Nucl Med Source Type: research
Outcome of patients with primary retroperitoneal solitary fibrous sarcoma.
CONCLUSION: RSFT is uncommon, slow-growing, and recrudescent tumors. Large tumor size and malignant pathology are associated with decreased DFS. Tumor size ≥ 10 cm independently predicts shortened DFS. PMID: 32140952 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Luo P, Wu Z, Chen S, Yang L, Cai W, Chen Y, Yan W, Wang C Tags: Int J Clin Oncol Source Type: research
Modern development of high-dose-rate brachytherapy.
Abstract Brachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law. High-dose-rate brachytherapy enables three-dimensional image guidance, and currently, tumor dose as well as doses of the surrounding normal structures can be evaluated accurately. High-dose-rate brachytherapy is the utmost precision radiation therapy even surpassing carbon ion therapy. Biological disadvantages of high-dose rate have been overcome by th...
Source: Clinical Prostate Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Itami J Tags: Jpn J Clin Oncol Source Type: research
VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions.
CONCLUSIONS: APBI with VMAT proved to be feasible and can be a valid alternative treatment option after BCS in selected early breast cancer pts according to ASTRO guidelines. A longer follow-up is needed to assess late toxicity. PMID: 32128672 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2020 Category: Cancer & Oncology Authors: La Rocca E, Lozza L, D' Ippolito E, Dispinzieri M, Giandini C, Bonfantini F, Valdagni R, Folli S, Pignoli E, Di Cosimo S, De Santis MC Tags: Clin Transl Oncol Source Type: research
Health-related quality of life in Japanese patients with prostate cancer following proton beam therapy: an institutional cohort study.
Abstract OBJECTIVE: Many treatment options have guaranteed long-term survival in patients with localized prostate cancer and health-related quality of life has become a greater concern for those patients. The purpose of this study was to reveal the health-related quality of life after proton beam therapy and to clarify the differences from other treatment modalities for prostate cancer. METHODS: Between January 2011 and April 2016, 583 patients were enrolled in the study and health-related quality of life outcomes using the Expanded Prostate Cancer Index Composite questionnaire were evaluated and compared wit...
Source: Clinical Prostate Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Matsukawa K, Arimura T, Orita M, Kondo H, Chuman I, Ogino T, Taira Y, Kudo T, Takamura N Tags: Jpn J Clin Oncol Source Type: research
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
CONCLUSION: In our study, the independent association of GPS with AP after initial active surveillance was not statistically significant, and there was no association with upgrading in surveillance biopsy. Adding GPS to a model containing PSAD and diagnostic GG did not significantly improve stratification of risk for AP over the clinical variables alone. PMID: 32130059 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF Tags: J Clin Oncol Source Type: research
Predictors of the regional variation of prostatectomy or radiotherapy: evidence from German cancer registries.
CONCLUSION: Treatment differs between East and West Germany and is associated with the presence of a radiotherapy or urology clinic. PMID: 32130481 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Medenwald D, Ferencz J, Vordermark D Tags: J Cancer Res Clin Oncol Source Type: research
Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
Abstract Hypothyroidism is a common adverse event of lenvatinib therapy for hepatocellular carcinoma (HCC), whereas thyrotoxicosis has rarely been reported in clinical trials. A 74-year-old man complaining of abdominal pain was found to have liver tumors and paraaortic lymphadenopathy. The intrahepatic lesions were diagnosed as HCC by angiography and treated with transcatheter arterial chemoembolization. Although localized prostate cancer was discovered incidentally, the etiology of paraaortic lymphadenopathy was assumed to be metastatic HCC. Lenvatinib 12 mg/day was started when his thyroid function tests we...
Source: Clinical Prostate Cancer - March 3, 2020 Category: Cancer & Oncology Authors: Suoh M, Fujii H, Nagata Y, Kotani K, Hagihara A, Enomoto M, Tamori A, Inaba M, Kawada N Tags: Clin J Gastroenterol Source Type: research
Perioperative therapies for urological cancers.
Abstract Although surgery with curative intent is critical for management of many localized cancers, multimodal therapy including neoadjuvant and adjuvant therapy has been introduced to increase the effectiveness of local control of surgery and prolong survival. However, strong evidence supporting the utility of such multimodal therapy is limited. The utility of perioperative chemotherapy has been extensively investigated in bladder cancer, and several randomized controlled trials have indicated the benefit of neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Regrettably, perioperative th...
Source: Clinical Prostate Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y Tags: Jpn J Clin Oncol Source Type: research
Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer.
CONCLUSION: H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease outcomes. PMID: 32119599 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Avkshtol V, Ruth KJ, Ross EA, Hallman MA, Greenberg RE, Price RA, Leachman B, Uzzo RG, Ma C, Chen D, Geynisman DM, Sobczak ML, Zhang E, Wong JK, Pollack A, Horwitz EM Tags: J Clin Oncol Source Type: research
Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
Abstract OBJECTIVE: To assess the use of the cell cycle progression (CCP) score versus actual risk stratification practice in making treatment decisions for prostate cancer patients with locally adverse pathology after radical prostatectomy (RP). PATIENTS AND METHODS: Men with adverse pathologic features, pT3 or positive surgical margins who underwent RP in 2010-2014 at Renji hospital were retrospectively analyzed. The primary outcome was biochemical recurrence (BCR) after RP. RNA was quantified from paraffin-embedded RP specimens. The CCP score was calculated as average expression of 31 CCP genes, normalized...
Source: Clinical Prostate Cancer - March 1, 2020 Category: Cancer & Oncology Authors: Shangguan X, Qian H, Jiang Z, Xin Z, Pan J, Dong B, Xue W Tags: J Cancer Res Clin Oncol Source Type: research
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
This study aimed to generate PB dose constraints based on dose-volume histograms (DVHs) in patients treated with prostate radiotherapy, and to identify clinical and dosimetric parameters that predict the risk of ED post prostate radiotherapy. Materials and methods: Penile bulb DVHs were generated for 276 patients treated within the randomised IGRT substudy of the multicentre randomised trial, CHHiP. Incidence of ED in relation to dose and randomised IGRT groups were evaluated using Wilcoxon rank sum, Chi-squared test and atlases of complication incidence. Youden index was used to find dose-volume constraints that disc...
Source: Clinical Prostate Cancer - February 21, 2020 Category: Cancer & Oncology Authors: Murray J, Gulliford S, Griffin C, Wilkins A, Syndikus I, Staffurth J, Panades M, Scrase C, Parker C, Khoo V, Dean J, Mayles H, Mayles P, Thomas S, Naismith O, Mossop H, Cruickshank C, Hall E, Dearnaley D, CHHiP Investigators Tags: Clin Transl Radiat Oncol Source Type: research
Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions.
Conclusion: We recommend the following dose volume objectives for the %RW in order to minimize the risk of LRB after 20-fraction MHRT: V32 ≤ 50%; V50 ≤ 25.8% and V60 ≤ 10%. PMID: 32072030 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 21, 2020 Category: Cancer & Oncology Authors: Sanguineti G, Faiella A, Farneti A, D'Urso P, Fuga V, Olivieri M, Giannarelli D, Marzi S, Iaccarino G, Landoni V Tags: Clin Transl Radiat Oncol Source Type: research
The ALERT-B questionnaire: A screening tool for the detection of gastroenterological late effects after radiotherapy for prostate cancer.
Abstract There is an increasing need to measure treatment-related side effects in normal tissues following cancer therapy. The ALERT-B (Assessment of Late Effects of RadioTherapy - Bowel) questionnaire is a screening tool that is composed of four items related specifically to bowel symptoms. Those patients that respond with a "yes" to any of these items are referred on to gastroenterologist in order to improve the long-term consequences of these side effects of radiological treatment. Here we wish to test the ability of this questionnaire to identify these subsequent gastroenterological complications by ...
Source: Clinical Prostate Cancer - February 21, 2020 Category: Cancer & Oncology Authors: Farnell DJJ, Staffurth J, Sivell S, Ahmedzai S, Andreyev J, Green J, Sanders DS, Ferguson CJ, Pickett S, Muls A, O'Shea R, Campbell SH, Taylor SE, Nelson A Tags: Clin Transl Radiat Oncol Source Type: research
Targeted and Systematic Biopsy for the Diagnosis and Management of Prostate Cancer - A Case for Lesion Targeted-Only Biopsies.
Abstract For much of the 1990s, transrectal ultrasound systematic biopsy was the standard approach for prostate cancer diagnosis. However, in the past decade multiparametric magnetic resonance imaging, multiparametric ultrasound and image fusion targeting have come to the fore. Here we present the state-of-the-art diagnostic strategies in prostate cancer detection and examine the case for target-only biopsy, as well as the benefits and limitations. PMID: 32035580 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 11, 2020 Category: Cancer & Oncology Authors: Tam JO, Ahmed HU Tags: Clin Oncol (R Coll Radiol) Source Type: research
Salvage Radiotherapy for Prostate Cancer.
Abstract For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (PSA) monitoring and the selected use of SRT has some advantages when compared with adjuvant radiotherapy. The most important one is avoidance of a potential overtreatment of patients who would never have disease progression, even in the presence of high-risk pathological features. The identification of a specific PSA cut-off seems to be incorrect. In patients ...
Source: Clinical Prostate Cancer - February 11, 2020 Category: Cancer & Oncology Authors: Rans K, Berghen C, Joniau S, De Meerleer G Tags: Clin Oncol (R Coll Radiol) Source Type: research
Current status and future prospective of focal therapy for localized prostate cancer: development of multiparametric MRI, MRI-TRUS fusion image-guided biopsy, and treatment modalities.
Abstract Multiparametric magnetic resonance imaging (mpMRI) has been increasingly used to diagnose clinically significant prostate cancer (csPC) because of its usefulness in combination with anatomic and functional data. MRI-targeted biopsy, such as MRI-transrectal ultrasound (TRUS) fusion image-guided prostate biopsy, has high accuracy in the detection and localization of csPC. This novel diagnostic technique contributes to the development of tailor-made medicine as focal therapy, which cures the csPC while preserving the anatomical structures related to urinary and sexual function. In the early days of focal the...
Source: Clinical Prostate Cancer - February 10, 2020 Category: Cancer & Oncology Authors: Shoji S, Hiraiwa S, Hanada I, Kim H, Nitta M, Hasegawa M, Kawamura Y, Hashida K, Tajiri T, Miyajima A Tags: Int J Clin Oncol Source Type: research
Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy.
L, Eklund M Abstract AIMS: Despite being one of the major pathways for the spread of malignant tumours, perineural invasion (PNI) has not conclusively been shown to have an independent prognostic value for prostate cancer. Prostatic biopsy constitutes the major pathology workload in prostate cancer and is the foundation for primary treatment decisions and for this reason we aimed to estimate the prognostic value of PNI in biopsies. METHODS: We followed 918 men who underwent radical prostatectomy (RP) from the prospective and population based STHLM3 study until biochemical recurrence with a median follow-up of...
Source: Clinical Prostate Cancer - February 7, 2020 Category: Cancer & Oncology Authors: Ström P, Nordström T, Delahunt B, Samaratunga H, Grönberg H, Egevad L, Eklund M Tags: J Clin Pathol Source Type: research
SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
CONCLUSION: SIRT7 plays an important role in the development and progression of human PCa and may be a promising prognostic marker for prostate cancer. PMID: 32019578 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Ding M, Jiang CY, Zhang Y, Zhao J, Han BM, Xia SJ Tags: J Exp Clin Cancer Res Source Type: research
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.
R, Martini JF, Miller DP, Moore C, Moy B, Pathak A, Philip R, Reese D, Royalty W, Ryder M, Sakul H, Salvatore LM, Schade A, Silvestro A, Simmons JK, Simons J, Singh Bhan S, Smalley MD, Somiari SB, Talasaz A, Tewari M, Tseng HR, Vinson J, Wells W, Welsh A, Grossman RL, Lee JSH, Leiman LC PMID: 32017048 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Febbo PG, Martin AM, Scher HI, Barrett JC, Beaver JA, Beresford PJ, Blumenthal GM, Bramlett K, Compton C, Dittamore R, Eberhard DA, Edelstein D, Godsey J, Gruen A, Hanlon SE, Hicks J, Hovelson D, Hullings M, Johann D, Johnson J, Kolatkar A, Kuhn P, Levine Tags: Clin Pharmacol Ther Source Type: research
Hypocalcaemia following denosumab in prostate cancer: a clinical review.
Abstract OBJECTIVE: Denosumab is often used in men with advanced prostate cancer to prevent skeletal related events, but can be associated with severe hypocalcaemia. Our objective was to review the pathophysiology, identify risk factors and provide recommendations for prevention and management of denosumab-associated hypocalcaemia. DESIGN: We reviewed the literature regarding denosumab-associated severe hypocalcaemia, defined as necessitating hospitalization for intravenous calcium treatment, in the context of prostate cancer. RESULTS: We identified 20 men with prostate cancer with severe denosumab-assoc...
Source: Clinical Prostate Cancer - February 4, 2020 Category: Cancer & Oncology Authors: Lau LH, Cliff ERS, Wong V, Wong H, Torkamani N, Eer A, Weickhardt A, Grossmann M Tags: Clin Endocrinol (Oxf) Source Type: research
Contribution of Surveillance Colonoscopy to Colorectal Cancer Prevention.
CONCLUSIONS: Using the recently developed metric of DTA, we estimated that surveillance colonoscopy during 10 years of follow up (in the PLCO colonoscopy cohort) prevented 30% of CRC cases. Because the methodology for estimation is indirect, the true effect is uncertain. PMID: 32017987 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 1, 2020 Category: Cancer & Oncology Authors: Pinsky PF, Schoen RE Tags: Clin Gastroenterol Hepatol Source Type: research
Eliminating microscopic lymph node metastasis by performing pelvic lymph node dissection during radical prostatectomy for prostate cancer.
Abstract The oncological benefit of pelvic lymph node dissection (PLND) for prostate cancer (PCa) remains unclear. The therapeutic effect of PLND on the elimination of microscopic metastases during radical prostatectomy (RP) for PCa was examined in the current study. A total of 348 Japanese patients with high- or intermediate-risk PCa without lymph node metastasis, who underwent antegrade RP at the Kyushu Cancer Center (Fukuoka, Japan) between August 1998 and May 2013 were retrospectively analyzed. The patients were divided into the standard (obturator + internal iliac nodes) group and the expanded (standard + add...
Source: Clinical Prostate Cancer - January 15, 2020 Category: Cancer & Oncology Authors: Furubayashi N, Negishi T, Uozumi T, Shiraishi K, Taguchi K, Shimokawa M, Nakamura M Tags: Mol Clin Oncol Source Type: research
Photodynamic Therapy for Photodamage, Actinic Keratosis, and Acne in the Cosmetic Practice.
Abstract Photodynamic therapy is the combination of the initial application of a photosensitive chemical on the skin and then using typically a blue filter light of varying spectrums. This treatment protocol has been more useful and functional than other chemical peels and lasers for a variety of conditions. There has been efficacy in antiviral treatments, such as herpetic lesions; malignant cancers of the head and neck; and lung, bladder, and skin cancers. It has been tested for prostate cancers, cervical cancer, colorectal cancer, lung cancer, breast cancer, esophageal cancer, stomach cancer, pancreatic cancer, ...
Source: Clinical Prostate Cancer - December 1, 2019 Category: Cancer & Oncology Authors: Moy LS, Frost D, Moy S Tags: Facial Plast Surg Clin North Am Source Type: research
Radiation Therapy for Prostate Cancer.
Abstract Randomized controlled trials provide evidence-driven clinical decision making in the management of newly diagnosed nonmetastatic and oligometastatic prostate cancer. Advances in technology (eg, multiparametric MRI, MR/transrectal ultrasound fusion biopsy, image-guided radiation therapy, stereotactic body radiation therapy) have transformed diagnosis and treatment of prostate cancer while improving cancer control and quality-of-life outcomes. Exciting breakthroughs are revealing possible new indications for radiotherapy, particularly with respect to oligometastatic prostate cancer. Ongoing studies using ne...
Source: Clinical Prostate Cancer - November 21, 2019 Category: Cancer & Oncology Authors: Kamran SC, D'Amico AV Tags: Hematol Oncol Clin North Am Source Type: research
A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy.
Conclusion: LDR-EBRT may provide more effective PSA control at 5 years compared with HDR-EBRT. Direct comparison of these treatments through randomised trials are recommended to investigate this hypothesis further. PMID: 31701035 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 11, 2019 Category: Cancer & Oncology Authors: Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Wilkinson C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM Tags: Clin Transl Radiat Oncol Source Type: research
Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol.
This study was registered with Japan Registry of Clinical Trials (jRCTs052190026). PMID: 31701044 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 11, 2019 Category: Cancer & Oncology Authors: Yamada Y, Shiaishi T, Ueno A, Kaneko M, Inoue Y, Fujihara A, Hongo F, Ukimura O Tags: Contemp Clin Trials Commun Source Type: research
177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.
We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. PMID: 31689280 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 8, 2019 Category: Cancer & Oncology Authors: Assadi M, Pirayesh E, Rekabpour SJ, Zohrabi F, Jafari E, Nabipour I, Esmaili A, Amini A, Ahmadzadehfar H Tags: Clin Nucl Med Source Type: research
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Abstract PURPOSE OF THE REPORT: The aim of the study was to prospectively compare performance of F-fluorocholine (FCH) and F-prostate-specific membrane antigen (PSMA)-1007 PET/CT in patients with biochemical relapse (BCR) of prostate cancer and low prostate-specific antigen levels. METHODS: We prospectively enrolled 40 BCR patients after radical treatment and prostate-specific antigen levels 2.0 ng/mL or less. F-FCH and F-PSMA-1007 PET/CT imaging was performed within a mean interval of 54 ± 21 days. Scans were done 87 ± 10 and 95 ± 12 minutes after injecting 248 ± 35 and 295 &plusm...
Source: Clinical Prostate Cancer - November 8, 2019 Category: Cancer & Oncology Authors: Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A Tags: Clin Nucl Med Source Type: research
Spontaneous healing of rectal penetration by SpaceOAR ® hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report.
Spontaneous healing of rectal penetration by SpaceOAR® hydrogel insertion during permanent iodine-125 implant brachytherapy: A case report. Mol Clin Oncol. 2019 Dec;11(6):580-582 Authors: Iinuma K, Mizutani K, Kato T, Nakane K, Tanaka H, Nakano M, Matsuo M, Koie T Abstract Radiation therapy with permanent iodine-125 implant brachytherapy is well established for curable prostate cancer. To maximize the therapeutic potential of brachytherapy, delivered radiation doses have been increased accompanied by refined intraoperative procedures of radioactive seeds placement. However, dose escalation is a do...
Source: Clinical Prostate Cancer - November 8, 2019 Category: Cancer & Oncology Authors: Iinuma K, Mizutani K, Kato T, Nakane K, Tanaka H, Nakano M, Matsuo M, Koie T Tags: Mol Clin Oncol Source Type: research
This article explores the most modern techniques and current uses of brachytherapy in the treatment of gynecological, prostate, breast, rectal, and skin cancers. PMID: 31668203 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 2, 2019 Category: Cancer & Oncology Authors: Otter SJ, Stewart AJ, Devlin PM Tags: Hematol Oncol Clin North Am Source Type: research
Proton beam therapy delivered using pencil beam scanning vs. passive scattering/uniform scanning for localized prostate cancer: Comparative toxicity analysis of PCG 001-09.
Abstract Background and purpose: Patient-level benefits of proton beam therapy (PBT) relative to photon therapy for prostate cancer (PC) continue to be the focus of debate. Although trials comparing the two modalities are underway, most are being conducted using "conventional" PBT (passive scattering/uniform scanning [PS/US]) rather than pencil beam scanning (PBS). The dosimetric benefits of PBS are well-known, but comparative data are limited. This analysis compares PBS toxicity rates with those of PS/US in a prospective multicenter registry. Methods: We evaluated acute/late gastrointestinal (GI) a...
Source: Clinical Prostate Cancer - October 29, 2019 Category: Cancer & Oncology Authors: Mishra MV, Khairnar R, Bentzen SM, Larson G, Tsai H, Sinesi C, Vargas C, Laramore G, Rossi C, Rosen L, Zhu M, Hartsell W Tags: Clin Transl Radiat Oncol Source Type: research
Biobehavioral effects of Tai Chi Qigong in men with prostate cancer: Study design of a three-arm randomized clinical trial.
Abstract Fatigue is often one of the most commonly reported symptoms in prostate cancer survivors, but it is also one of the least understood cancer-related symptoms. Fatigue is associated with psychological distress, disruptions in sleep quality, and impairments in health-related quality of life. Moreover, inflammatory processes and changes related to the hypothalamic-pituitary-adrenal (HPA) axis and/or autonomic nervous system may also play a role in cancer-related fatigue. Thus, effective treatments for fatigue in prostate cancer survivors represent a current unmet need. Prior research has shown that Tai Chi Qi...
Source: Clinical Prostate Cancer - October 29, 2019 Category: Cancer & Oncology Authors: Kinney AY, Blair CK, Guest DD, Ani JK, Harding EM, Amorim F, Boyce T, Rodman J, Ford CG, Schwartz M, Rosenberg L, Foran O, Gardner J, Lin Y, Arap W, Irwin MR Tags: Contemp Clin Trials Commun Source Type: research
Prostate mpMRI in the UK: the state of the nation.
Abstract The diagnosis of prostate cancer has changed. Improved magnetic resonance imaging (MRI) technology with diffusion-weighted imaging has led to the use of multiparametric MRI (mpMRI) before biopsy in patients suspected of having prostate cancer. This has the advantage that patients with a negative mpMRI may not need biopsy, therefore avoiding the risk of complications. Those in whom mpMRI is positive can have targeted biopsies with a higher probability of diagnosing clinically significant cancer. Prostate Cancer UK (PCUK) and the British Society of Urogenital Radiology submitted a Freedom of Information (FO...
Source: Clinical Prostate Cancer - October 20, 2019 Category: Cancer & Oncology Authors: Davies C, Castle JT, Stalbow K, Haslam PJ Tags: Clin Radiol Source Type: research
Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases.
Abstract The UK National Institute for Health and Care Excellence (NICE) 2019 "Prostate cancer: diagnosis and management" guidelines have recommended that all patients suspected of prostate cancer undergo multiparametric magnetic resonance imaging (mpMRI) prior to biopsy. The Likert scoring system is advocated for mpMRI reporting based on multicentre studies that have demonstrated its effectiveness within the National Health Service (NHS). In recent years, there has been considerable drive towards standardised prostate reporting, which led to the development of "Prostate Imaging-Reporting And Data S...
Source: Clinical Prostate Cancer - October 20, 2019 Category: Cancer & Oncology Authors: Latifoltojar A, Appayya MB, Barrett T, Punwani S Tags: Clin Radiol Source Type: research